An Open-Label, Expanded Access Treatment Protocol to Provide Access to Vamorolone Treatment for Boys with Duchenne Muscular Dystrophy who Have Completed the Long-Term Extension (VBP15-LTE) or VBP15-004 Studies

This study is intended to provide continued access to vamorolone for subjects in the United States who have completed the VBP15-LTE or VBP15-004 protocols (and are thereby ineligible to enroll in another trial of vamorolone therapy), during the time a new drug application for vamorolone is under preparation and review. Participants who have completed the Long Term Extension study or Phase IIb study are eligible to enroll. To learn more about the study eligibility and participating sites please contact Reveragen at laurie.conklin@reveragen.com.